• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor.静脉血栓形成且纤维蛋白溶解功能缺陷患者的两种不同机制:纤溶酶原激活物浓度低或纤溶酶原激活物抑制剂浓度升高。
Br Med J (Clin Res Ed). 1985 May 18;290(6480):1453-6. doi: 10.1136/bmj.290.6480.1453.
2
Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.青少年血液纤溶成分的年龄依赖性以及低剂量口服避孕药对青少年凝血和纤溶的影响。
Thromb Haemost. 1988 Dec 22;60(3):361-4.
3
Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis.静脉淤滞后残余纤溶酶原激活物抑制剂活性作为低纤溶的标准:对83例确诊深静脉血栓形成患者的研究
Blood. 1988 Aug;72(2):601-5.
4
The role of the fibrinolytic system in deep vein thrombosis.纤维蛋白溶解系统在深静脉血栓形成中的作用。
J Lab Clin Med. 1985 Feb;105(2):265-70.
5
Thrombosis after hip replacement. Relationship to the fibrinolytic system.髋关节置换术后的血栓形成。与纤维蛋白溶解系统的关系。
Acta Orthop Scand. 1989 Apr;60(2):159-63. doi: 10.3109/17453678909149244.
6
[Poor fibrinolytic response to venous occlusion: defect of endothelial cells or plasma interference?].[对静脉闭塞的纤溶反应不佳:内皮细胞缺陷还是血浆干扰?]
Schweiz Med Wochenschr. 1983 Oct 8;113(40):1462-4.
7
Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.冠状动脉疾病患者的纤溶酶原激活物抑制剂活性及其他纤溶变量
Br Heart J. 1988 May;59(5):535-41. doi: 10.1136/hrt.59.5.535.
8
Relationship between age and plasma t-PA, PA-inhibitor, and PA activity.年龄与血浆组织型纤溶酶原激活物、纤溶酶原激活物抑制剂及纤溶酶原激活物活性之间的关系。
Thromb Res. 1987 Jun 1;46(5):625-33. doi: 10.1016/0049-3848(87)90264-7.
9
Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura.健康与疾病中的纤维蛋白溶解:血栓性血小板减少性紫癜中纤溶酶原激活物、纤溶酶原激活物抑制剂和蛋白C的异常水平
J Lab Clin Med. 1986 Nov;108(5):415-22.
10
Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.
Thromb Haemost. 1987 Feb 3;57(1):67-72.

引用本文的文献

1
Regulation of macrophage fibrinolysis during venous thrombus resolution.调控巨噬细胞纤溶在静脉血栓溶解中的作用。
Thromb Res. 2024 Nov;243:109149. doi: 10.1016/j.thromres.2024.109149. Epub 2024 Sep 14.
2
Targeting Fibrinolytic Inhibition for Venous Thromboembolism Treatment: Overview of an Emerging Therapeutic Approach.靶向纤维蛋白溶解抑制治疗静脉血栓栓塞症:一种新兴治疗方法概述。
Circulation. 2024 Sep 10;150(11):884-898. doi: 10.1161/CIRCULATIONAHA.124.069728. Epub 2024 Sep 9.
3
Chemical Adjustment of Fibrinolysis.纤维蛋白溶解的化学调节
Pharmaceuticals (Basel). 2024 Jan 10;17(1):92. doi: 10.3390/ph17010092.
4
Fibrinolysis Shutdown and Hypofibrinolysis Are Not Synonymous Terms: The Clinical Significance of Differentiating Low Fibrinolytic States.纤溶抑制和低纤溶不是同义词:区分低纤溶状态的临床意义。
Semin Thromb Hemost. 2023 Jul;49(5):433-443. doi: 10.1055/s-0042-1758057. Epub 2022 Nov 1.
5
Pathophysiological Aspects of Aging in Venous Thromboembolism: An Update.衰老在静脉血栓栓塞症中的病理生理学:更新。
Medicina (Kaunas). 2022 Aug 10;58(8):1078. doi: 10.3390/medicina58081078.
6
Fibrinolysis and Inflammation in Venous Thrombus Resolution.纤维蛋白溶解与静脉血栓溶解中的炎症反应。
Front Immunol. 2019 Jun 14;10:1348. doi: 10.3389/fimmu.2019.01348. eCollection 2019.
7
CEMIP (KIAA1199) induces a fibrosis-like process in osteoarthritic chondrocytes.CEMIP(KIAA1199)可诱导骨关节炎软骨细胞产生类似纤维化的过程。
Cell Death Dis. 2019 Feb 4;10(2):103. doi: 10.1038/s41419-019-1377-8.
8
Serpins in Venous Thrombosis and Venous Thrombus Resolution.丝氨酸蛋白酶抑制剂与静脉血栓形成及静脉血栓溶解
Methods Mol Biol. 2018;1826:197-211. doi: 10.1007/978-1-4939-8645-3_13.
9
Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease.1型纤溶酶原激活物抑制剂对冠心病的因果效应
J Am Heart Assoc. 2017 May 26;6(6):e004918. doi: 10.1161/JAHA.116.004918.
10
Enhanced venous thrombus resolution in plasminogen activator inhibitor type-2 deficient mice.2型纤溶酶原激活物抑制剂缺陷小鼠的静脉血栓溶解增强
J Thromb Haemost. 2014 Oct;12(10):1706-16. doi: 10.1111/jth.12657. Epub 2014 Sep 30.

本文引用的文献

1
Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system.一名年轻男性患有严重血栓性疾病,伴有骨髓和骨骼改变,且纤溶系统中一种抑制剂含量较高。
Acta Med Scand. 1961 Mar;169:323-37. doi: 10.1111/j.0954-6820.1961.tb07838.x.
2
Relationship between tissue plasminogen activator and the activators in blood and vascular wall.组织型纤溶酶原激活剂与血液及血管壁中的激活剂之间的关系。
Thromb Res. 1980 Jun 15;18(6):815-30. doi: 10.1016/0049-3848(80)90204-2.
3
[Study of coagulation and fibrinolysis in 131 cases of recurrent deep vein thrombosis].131例复发性深静脉血栓形成患者的凝血与纤溶研究
Nouv Rev Fr Hematol (1978). 1982;24(3):205-9.
4
Studies of the blood plasminogen activator induced by 1-desamino-8-D-arginine vasopressin with observations in von Willebrand's disease.1-去氨基-8-D-精氨酸加压素诱导的血浆纤溶酶原激活物的研究及对血管性血友病的观察
Proc Soc Exp Biol Med. 1982 Jun;170(2):126-32. doi: 10.3181/00379727-170-41407.
5
A family with reduced plasminogen activator activity in blood associated with recurrent venous thrombosis.一个血液中纤溶酶原激活物活性降低且与复发性静脉血栓形成相关的家族。
Scand J Haematol. 1982 Sep;29(3):217-23. doi: 10.1111/j.1600-0609.1982.tb00586.x.
6
Plasminogen activator activity of superficial veins in acute deep venous thrombosis.急性深静脉血栓形成时浅表静脉的纤溶酶原激活物活性
Vasa. 1982;11(3):174-7.
7
Deep venous thrombosis of the arm: a study of coagulation and fibrinolysis.手臂深静脉血栓形成:凝血与纤溶研究
Br Med J (Clin Res Ed). 1981 Jul 25;283(6286):265-7. doi: 10.1136/bmj.283.6286.265.
8
Clinical relevance of antithrombin III.抗凝血酶III的临床相关性。
Semin Thromb Hemost. 1982 Oct;8(4):276-87. doi: 10.1055/s-2007-1005058.
9
Immunological characterisation of plasminogen activators in the human vessel wall.人血管壁中纤溶酶原激活剂的免疫学特性分析
J Clin Pathol. 1983 Sep;36(9):1046-9. doi: 10.1136/jcp.36.9.1046.
10
Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex.
Proc Natl Acad Sci U S A. 1983 Nov;80(22):6804-8. doi: 10.1073/pnas.80.22.6804.

静脉血栓形成且纤维蛋白溶解功能缺陷患者的两种不同机制:纤溶酶原激活物浓度低或纤溶酶原激活物抑制剂浓度升高。

Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor.

作者信息

Nilsson I M, Ljungnér H, Tengborn L

出版信息

Br Med J (Clin Res Ed). 1985 May 18;290(6480):1453-6. doi: 10.1136/bmj.290.6480.1453.

DOI:10.1136/bmj.290.6480.1453
PMID:3922531
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1415704/
Abstract

Fibrinolytic components after venous occlusion and concentrations of tissue plasminogen activator inhibitor were studied in 100 consecutive patients with confirmed recurrent deep vein thrombosis or pulmonary embolism. After 20 minutes of venous occlusion the fibrinolytic response was decreased in 33 patients, as measured both amidolytically with S-2251 and on fibrin plates. Two different mechanisms responsible for the poor fibrinolytic response could be distinguished. Twenty two of the patients in whom the response was poor released normal amounts of tissue plasminogen activator antigen, as assayed by immunoradiometric assay, but had appreciably increased concentrations of tissue plasminogen activator inhibitor. The 11 other patients in whom the response was poor had both low tissue plasminogen activator activities and low tissue plasminogen activator antigen concentrations but normal concentrations of tissue plasminogen activator inhibitor. The results show not only that defective synthesis or release of tissue plasminogen activator may be important in the pathogenesis of venous thrombosis but also that a large group of patients with thrombosis have an increased concentration of the inhibitor to tissue plasminogen activator.

摘要

对100例确诊为复发性深静脉血栓形成或肺栓塞的连续患者,研究了静脉闭塞后的纤溶成分及组织型纤溶酶原激活物抑制剂的浓度。静脉闭塞20分钟后,33例患者的纤溶反应降低,这是通过用S - 2251进行酰胺分解测定以及在纤维蛋白平板上测定得出的。可区分出导致纤溶反应不佳的两种不同机制。在纤溶反应不佳的患者中,22例通过免疫放射测定法检测,释放的组织型纤溶酶原激活物抗原量正常,但组织型纤溶酶原激活物抑制剂的浓度明显升高。另外11例纤溶反应不佳的患者,其组织型纤溶酶原激活物活性和组织型纤溶酶原激活物抗原浓度均较低,但组织型纤溶酶原激活物抑制剂浓度正常。结果表明,不仅组织型纤溶酶原激活物的合成或释放缺陷在静脉血栓形成的发病机制中可能很重要,而且一大群血栓形成患者的组织型纤溶酶原激活物抑制剂浓度升高。